What is it about?

Upacicalcet reduced serum iPTH levels, serum FGF23 levels, and bone metabolism marker levels in patients with secondary hyperparathyroidism on dialysis; Upacicalcet-induced gastrointestinal disturbances and hypocalcemia were uncommon. Thus, Upacicalcet may be an effective and safe calcimimetic agent in the management of secondary hyperparathyroidism.

Featured Image

Read the Original

This page is a summary of: Efficacy and Safety of Upacicalcet in Hemodialysis Patients with Secondary Hyperparathyroidism, Clinical Journal of the American Society of Nephrology, September 2023, Wolters Kluwer Health,
DOI: 10.2215/cjn.0000000000000253.
You can read the full text:

Read

Contributors

The following have contributed to this page